Manke Isaac's Form 4 filing
OnKure Therapeutics, Inc. (OKUR) · filed Aug 11, 2026
- Accession no.
- 0001622769-26-000002
- Filed
- Aug 11, 2026, 4:39 PM ET
- Trade date
- Aug 7, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 derivative transactions. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001622769-26-000006 (Aug 13, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Manke IsaacCIK 0001622769 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Class A Common Stock | AGrant or awardAcquired | +300,000 | $0.00 | $0 | 300,000 | Direct | |
| Aug 7, 2026 | Class A Common Stock | DReturned to the companyDisposed | −15,300 | –F3,F4 | – | 0 | Direct | |
| Aug 7, 2026 | Class A Common Stock | AGrant or awardAcquired | +15,300 | –F3,F4 | – | 15,300 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.
Referenced by the price of 2 transactions in Table II.
- F4
Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.
Referenced by the price of 2 transactions in Table II.